Investors may have lost sight of the fact that Eli Lilly has at least three other product candidates with the potential to launch in 2016-2017, Deutsche Bank analyst Gregg Gilbert tells investors in a research note. Positive Phase 3 data for the company's Alzheimer's treatment candidate solanezumab in late 2016 is crucial to the stock's performance over the next year, but there is more to Lilly's pipeline, Gilbert points out. He highlights abemaciclib for breast and other cancers, baricitinib for rheumatoid arthritis and ixekizumab for psoriasis. The analyst hopes his sales estimates for the three products in aggregate, $2.5B in 2020, proves conservative. He keeps a Buy rating on Lilly with a $99 price target. The drug manufacturer closed Friday down $1.43 to $84.79.

Shares of sleep apnea device makers ResMed (RMD) and Inspire Medical (INSP) are moving in opposite directions after Eli Lilly (LLY) announced topline results of the SURMOUNT-OSA Phase 3 clinical trials, showing tirzepatide injection significantly reduced the apnea-hypopnea index, or AHI, compared to placebo, achieving the primary endpoints of the studies. After initially moving... To see the rest of the story go to thefly.com. See Story Here

Shares of sleep apnea device makers ResMed (RMD) and Inspire Medical (INSP) are slipping in early trading after Eli Lilly (LLY) announced topline results of the SURMOUNT-OSA phase 3 clinical trials that showed tirzepatide injection significantly reduced the apnea-hypopnea index, or AHI, compared to placebo, achieving the primary endpoints of the studies. SURMOUNT-OSA Study 1 evaluated tirzepatide, which Lilly identifies as "the only approved GIP and GLP-1 treatment for chronic weight management, commercialized as Zepbound in the U.S. and Mounjaro in some global markets outside the U.S.," in adults with moderate-to-severe obstructive sleep apnea, or OSA, and obesity who were not on positive airway pressure, or PAP, therapy for 52 weeks. In Wednesday pre-market trading, ResMed shares are down about 3% to $180, while Inspire shares have slipped about 1% to $220.